Directors Dealings / Market Share Purchases
Directors Dealings / Market Share Purchases
Oxford, UK - 29 April 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Catherine Moukheibir, a Non-Executive Director of the Company, has purchased shares in the Company.
As stated in the Oxford Biomedica 2021 Remuneration Policy which was approved at the 2021 Annual General Meeting, an additional fee of up to £50,000 per annum may be paid to any Non-Executive Director recruited from or based outside of the UK to reflect market levels of remuneration based for Non-Executive Directors not based in the UK, subject to their agreement that the after tax amount of this additional fee will be used to acquire Oxford Biomedica shares at market value, which must be retained for at least 12 months from acquisition.
Catherine Moukheibir has purchased 2,467 ordinary shares of 50p each ("Ordinary Shares") in the Company on 29 April 2022 on the London Stock Exchange at a price of 570.9p under the terms of a market purchase agreement. Following this purchase Catherine Moukheibir holds 2,467 Ordinary Shares representing 0.002% of the Company.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
|
1. |
Details of the person discharging material responsibilities/person closely associated
|
||
|
a. |
Name |
Catherine Moukheibir
|
|
|
2. |
Reason for the notification
|
||
|
a. |
Position/status |
Non-Executive Director |
|
|
b. |
Initial notification /amendment |
Initial notification
|
|
|
3. |
Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
|
||
|
a. |
Name |
Oxford Biomedica plc
|
|
|
b. |
Legal Entity Identifier |
213800S1GVQNXQ15K851
|
|
|
4. |
Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||
|
a. |
Description of the financial instrument, type of instrument identification code |
Oxford Biomedica plc Ordinary Shares of 50p each
GB00BDFBVT43
|
|
|
b. |
Nature of the transaction |
Purchase of ordinary shares
|
|
|
c. |
Currency |
GBP - British Pound
|
|
|
d. |
Price(s) and volume(s) |
Price(s)
|
Volume(s) |
|
£5.71 |
2,467 |
||
|
|
|
||
|
e. |
Aggregated information · Aggregated volume · Price · Aggregated total
|
2,467
5.70903 14,084.18
|
|
|
f. |
Date of the transaction |
2022-04-29 |
|
|
g. |
Place of the transaction |
London Stock Exchange, Main Market (XLON)
|
|
-Ends-
|
For further information, please contact: |
|
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.
Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com .
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund